Epidemiology and Outcome of Primary Central Nervous System Tumors Treated at King Hussein Cancer Center

被引:0
|
作者
Al-Hussaini, Maysa [1 ,2 ]
Al-Ani, Abdallah [3 ]
Amarin, Justin Z. [3 ]
Al Sharie, Sarah [3 ]
Obeidat, Mouness [4 ]
Musharbash, Awni [4 ]
Al Shurbaji, Amer A. [4 ]
Ibrahimi, Ahmad Kh. [5 ]
Al-Mousa, Abdellatif [5 ]
Sarhan, Nasim [5 ]
Amayiri, Nisreen [6 ]
Amarin, Rula [7 ]
Alawabdeh, Tala [7 ]
Alzoubi, Qasem [8 ]
Abu Laban, Dima [8 ]
Maraqa, Bayan [2 ]
Jamal, Khaled [3 ]
Mansour, Asem [8 ]
机构
[1] King Hussein Canc Ctr, Dept Cell Therapy & Appl Genom, Amman 11941, Jordan
[2] King Hussein Canc Ctr, Dept Pathol & Lab Med, Amman 11941, Jordan
[3] King Hussein Canc Ctr, Off Sci Affairs & Res, Amman 11941, Jordan
[4] King Hussein Canc Ctr, Dept Surg, Amman 11941, Jordan
[5] King Hussein Canc Ctr, Dept Radiat Oncol, Amman 11941, Jordan
[6] King Hussein Canc Ctr, Dept Pediat, Amman 11941, Jordan
[7] King Hussein Canc Ctr, Dept Internal Med, Amman 11941, Jordan
[8] King Hussein Canc Ctr, Dept Radiol, Amman 11941, Jordan
关键词
central nervous system tumors; epidemiology; survival rates; BRAIN-TUMORS; MALIGNANT BRAIN; SEX-DIFFERENCES; SURVIVAL; MEDULLOBLASTOMA; CHILDREN; RISK;
D O I
10.3390/cancers17040590
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives: Primary central nervous system (CNS) tumors are often associated with relatively poor outcomes. Data on the epidemiology and outcome of CNS tumors in Jordan are scarce. We aim to report the epidemiology and outcome of primary CNS tumors of patients managed at a comprehensive cancer care center in Jordan. Methods: We performed a retrospective chart review of all Jordanian patients with a primary CNS tumor diagnosis who were managed at the center between July 2003 and June 2019. We included all entities described in the 2021 CNS WHO classification system, in addition to pituitary neuroendocrine tumors (PitNETs). We used the Kaplan-Meier method to estimate the 1-year, 2-year, and 5-year overall survival (OS) rates for each entity. Results and Findings: We included 2094 cases. The numbers of pediatrics and adults were 652 (31.1%) and 1442 (68.9%), respectively. The three most common groups of tumors were "gliomas, glioneuronal tumors, and neuronal tumors" (n = 1200 [57.30%]), followed by meningiomas (n = 261 [12.5%]), embryonal tumors (n = 234 [11.2%]). The three most common tumor families were adult-type diffuse gliomas (n = 709 [33.8%]), medulloblastoma (n = 199 [9.5%]), and circumscribed astrocytic gliomas (n = 183 [8.7%]). The median survival for the entire cohort was 97 months (95CI; 81-112). Survival was significantly worse for males and adults compared to their respective counterparts. Among the most common tumor group, "gliomas, glioneuronal tumors, and neuronal tumors", OS rates for adult-type diffuse gliomas were significantly lower than all other types. Overall, adult gliomas with IDH-mutations had a survival advantage over wildtype cases (IDH-mutant 1-year OS, 89% [82-97%] vs. IDH-wildtype 1-year OS, 60% [52-70%]; p < 0.001). Conclusions: We present a detailed analysis of the primary CNS tumors diagnosed in the largest cancer center in Jordan between 2003 and 2019. We compared the epidemiology and overall survival of these patients to worldwide estimates and found the epidemiology and outcome of these tumors comparable to worldwide trends.
引用
收藏
页数:23
相关论文
共 50 条
  • [31] Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience
    Susam-Sen, Hilal
    Varan, Ali
    Bajin, Inci
    Gocmen, Rahsan
    Aydin, Burca
    Yalcin, Bilgehan
    Kurucu, Nilgun
    Kutluk, Tezer
    Bayhan, Turhan
    Akyuz, Canan
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2021, 394 (08) : 1769 - 1777
  • [32] The clinical characteristics and treatment outcome of 57 children and adolescents with primary central nervous system germ cell tumors
    Sun, Xiao-Fei
    Zhang, Fei
    Zhen, Zi-Jun
    Yang, Qun-Ying
    Xia, Yun-Fei
    Wu, Shao-Xiong
    Zhu, Jia
    Lu, Su-Ying
    Wang, Juan
    Sun, Fei-Fei
    Cai, Rui-Qing
    Chen, Yan
    Li, Peng-Fei
    CHINESE JOURNAL OF CANCER, 2014, 33 (08) : 395 - 401
  • [33] Prevalence of primary central nervous system tumors in Iran: a retrospective study
    Harandi, Ali Amini
    Zarifi, Elham
    Shahmohammadi, Mohammad Reza
    UNIVERSA MEDICINA, 2023, 42 (02) : 206 - 213
  • [34] Organ Donation and Primary Central Nervous System Tumors
    Cacciatori, A.
    Godino, M.
    Bengochea, M.
    Prinzo, H.
    TRANSPLANTATION PROCEEDINGS, 2020, 52 (04) : 1024 - 1029
  • [35] The use of bevacizumab in primary malignant tumors of the central nervous system: A single-center experience
    Pehlivan, Metin
    Ekenel, Meltem
    MEDICINE, 2023, 102 (30) : E34286
  • [36] Pediatric central nervous system tumors: review of a single Portuguese institution
    Santos, Maria M.
    Faria, Claudia C.
    Miguens, Jos
    CHILDS NERVOUS SYSTEM, 2016, 32 (07) : 1227 - 1236
  • [37] Retrospective Evaluation of Childhood Central Nervous System Tumors Followed in a Pediatric Hematology Oncology Center: A Single Center Experience
    Genc, Asli
    Yazal Erdem, Arzu
    Emir, Suna
    Ozyoruk, Derya
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2024, 34 (01): : 45 - 51
  • [38] Descriptive epidemiology of primary malignant and non-malignant central nervous tumors in Spain: Results from the Girona Cancer Registry (1994-2013)
    Fuentes-Raspall, Rafael
    Solans, Marta
    Roca-Barcelo, Aina
    Vilardell, Loreto
    Puigdemont, Montse
    del Barco, Sonia
    Comas, Raquel
    Garcia-Velasco, Adelaida
    Astudillo, Aurora
    Carme Carmona-Garcia, Ma
    Marcos-Gragera, Rafael
    CANCER EPIDEMIOLOGY, 2017, 50 : 1 - 8
  • [39] Multiple primary tumors involving cancer of the brain and central nervous system as the first or subsequent cancer
    Inskip, PD
    CANCER, 2003, 98 (03) : 562 - 570
  • [40] Outcome of children and adolescents with central nervous system tumors in phase I trials
    Carceller, Fernando
    Bautista, Francisco
    Jimenez, Irene
    Hladun-Alvaro, Raquel
    Giraud, Cecile
    Bergamaschi, Luca
    Dandapani, Madhumita
    Aerts, Isabelle
    Doz, Francois
    Frappaz, Didier
    Casanova, Michela
    Morland, Bruce
    Hargrave, Darren R.
    Vassal, Gilles
    Pearson, Andrew D. J.
    Geoerger, Birgit
    Moreno, Lucas
    Marshall, Lynley V.
    JOURNAL OF NEURO-ONCOLOGY, 2018, 137 (01) : 83 - 92